ILMN
Illumina, Inc.
Diagnostics & Research · Healthcare · United States
192.64
close · 2026-08-13
value
25
cheaper than peers25
quality
68
stronger fundamentals68
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 26.50× | 38 |
| price to sales | 6.32× | 35 |
| forward P/E | 31.60× | 34 |
| price to book | 10.25× | 25 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 32.3% | 90 |
| operating margin | 21.1% | 87 |
| revenue growth | 9.4% | 34 |
| debt to equity | 89.0% | 25 |
4 of 4 measures available
Facts
| market cap | $29B |
| free cash flow | $797.6M |
| employees | 8,600 |
| first trade | 2000-07-28 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-08-07 |